Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
NCT00984113 · Portola Pharmaceuticals · PHASE1 · terminated · last registry update 2023-08-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “For administrative reasons. Enrollment was sufficient to have statistical power without compromising the integrity of the study data” | – | Registry record, Portola Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against P2RY12 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-16Phase 3 first posted: Beijing Tiantan Hospital, rhTNK-tPA + Control group (Aspirin combined with clopidogrel) (NCT06414499)
- 2024-05-06Results posted on the registry: University of Maryland, Baltimore, Clopidogrel + Ticagrelor (NCT03161678)
- 2024-04-25Also stopped (terminated): Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Absence of vitamin K antagonist (NCT01556659)
- 2024-04-23Results posted on the registry: Coherex Medical, Anticoagulation or Clopidogrel (NCT03204695)
- 2024-04-23Also stopped (terminated): Coherex Medical, Anticoagulation or Clopidogrel (NCT03204695)
- 2024-04-22Also stopped (terminated): Samsung Medical Center, Clopidogrel + Ticagrelor (NCT03119012)
- 2024-04-11Phase 3 first posted: Kafrelsheikh University, Atorvastatin 40 Mg Oral Tablet + Rosuvastatin 20mg (NCT06360120)
- 2024-04-10Phase 3 first posted: Kafrelsheikh University, Atorvastatin 40mg + Rosuvastatin 20mg (NCT06358313)
- 2024-04-08Phase 3 first posted: The George Institute, Standard-dose intravenous tenecteplase + Low-dose intravenous tenecteplase (NCT06352632)
- 2024-03-20Results posted on the registry: University of Florida, Cangrelor + Prasugrel (NCT04668144)
- 2024-03-19Phase 3 first posted: National Institute of Cardiovascular Diseases, Pakistan, Ticagrelor 90 MG + Clopidogrel (NCT06318481)
- 2024-02-21Results posted on the registry: Mayo Clinic, Clopidogrel + Prasugrel (NCT05223335)
- 2024-02-05Phase 3 first posted: Kafrelsheikh University, Clopidogrel tablet + Cilostazol 100 MG (NCT06242132)
- 2024-02-05Phase 3 first posted: Kafrelsheikh University, Clopidogrel tablet + Cilostazol 100 MG (NCT06242145)
- 2024-02-05Results posted on the registry: Pfizer, PF-07081532 + Clopidogrel (NCT04305587)
- 2024-02-02Phase 3 first posted: Beijing Tiantan Hospital, Tirofiban + aspirin, clopidogrel (NCT06238115)
- 2024-01-19Results posted on the registry: The TIMI Study Group, Unfractionated Heparin IV + Enoxaparin 1 mg/kg (NCT04409834)
- 2024-01-18Phase 3 first posted: Kafrelsheikh University, Citicoline 2000 + citocoline 1000 (NCT06210646)
- 2024-01-11Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Cilostazol 100 MG (NCT06202755)
- 2023-12-11Phase 3 first posted: Navamindradhiraj University, Aspirin 81Mg Ec Tab + Clopidogrel (NCT06165068)
- 2023-11-07Phase 3 first posted: Kafrelsheikh University, Ticagrelor 90 MG + Clopidogrel (NCT06120725)
- 2023-10-13Phase 3 first posted: Steno Diabetes Center Copenhagen, Aspirin tablet + Semaglutide (NCT06082063)
- 2023-09-14Phase 3 first posted: Peking Union Medical College Hospital, Tirofiban + Aspirin tablet (NCT06037889)
- 2023-09-08Also stopped (terminated): Dexa Medica Group, DLBS1033 + Placebo (NCT02976701)
- 2023-09-01Phase 3 first posted: Lady Reading Hospital, Pakistan, Clopidogrel Bisulfate 75Mg Tab (NCT06021990)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision